Mark T Reding (Mark Reding, M T Reding)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 14

Top Topics

Atrial Fibrillation

Top Venues

Haemophilia : the official journal of the World Federation of Hemophilia

Therapeutic advances in hematology

JMIR medical informatics

This page only lists publications with an associated author ORCID identifier.

Publications

Keerthy Joseph, Adam Cuker, Skye Peltier, Mark T Reding, Dunlei Cheng, Xiaoyan Han, Allyson M Pishko
The impact of obesity on chronic pain in patients with haemophilia: A multicentre retrospective analysis. Haemophilia : the official journal of the World Federation of Hemophilia (2024)
Keerthy Joseph, Adam Cuker, Skye Peltier, Mark T Reding, Dunlei Cheng, Xiaoyan Han, Allyson M Pishko
The impact of obesity on chronic pain in patients with haemophilia: A multicentre retrospective analysis. Haemophilia : the official journal of the World Federation of Hemophilia 30 (2) (2024)
Keerthy Joseph, Adam Cuker, Skye Peltier, Mark T Reding, Dunlei Cheng, Xiaoyan Han, Allyson M Pishko
The impact of obesity on chronic pain in patients with haemophilia: A multicentre retrospective analysis. Haemophilia : the official journal of the World Federation of Hemophilia 30 (2) (2024)
Mark T Reding, Ingrid Pabinger, Pål Andrè Holme, Monika Maas Enriquez, Maria Elisa Mancuso, Shadan Lalezari, Wolfgang Miesbach, Giovanni Di Minno, Robert Klamroth, Cedric Hermans
Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study. Therapeutic advances in hematology 14 (2023)
Mark T Reding, Ingrid Pabinger, Pål Andrè Holme, Monika Maas Enriquez, Maria Elisa Mancuso, Shadan Lalezari, Wolfgang Miesbach, Giovanni Di Minno, Robert Klamroth, Cedric Hermans
Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study. Therapeutic advances in hematology 14 (2023)
Mark T Reding, Ingrid Pabinger, Pål Andrè Holme, Monika Maas Enriquez, Maria Elisa Mancuso, Shadan Lalezari, Wolfgang Miesbach, Giovanni Di Minno, Robert Klamroth, Cedric Hermans
Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study. Therapeutic advances in hematology 14 (2023)
Alfonso Iorio, Christoph Königs, Mark T Reding, Dawn Rotellini, Mark W Skinner, Maria Elisa Mancuso, Erik Berntorp
Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia: A review of the literature. Haemophilia : the official journal of the World Federation of Hemophilia (2022)
Elena Santagostino, Shadan Lalezari, Mark T Reding, Jonathan Ducore, Heng Joo Ng, Lone H Poulsen, Lisa A Michaels, Camila Linardi
Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during minor surgical procedures in patients with severe haemophilia A. Haemophilia : the official journal of the World Federation of Hemophilia 27 (4) (2021)
Surbhi Shah, Sean Switzer, Nathan D Shippee, Pamela Wogensen, Kathryn Kosednar, Emma K Jones, Deborah L Pestka, Sameer Badlani, Mary Butler, Brittin Wagner, Katie M White, Joshua Rhein, Bradley Benson, Mark T Reding, Michael Usher, Genevieve B Melton, Christopher James Tignanelli
Implementation of an Anticoagulation Practice Guideline for COVID-19 via a Clinical Decision Support System in a Large Academic Health System and Its Evaluation: Observational Study. JMIR medical informatics 9 (11) (2021)
Martin Sanabria, María Teresa Álvarez Román, Giancarlo Castaman, Maissaa Janbain, Tadashi Matsushita, Karina Meijer, Johannes Oldenburg, Sabine Friedl, Mark T Reding
Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A. BMJ open 11 (9) (2021)
Miguel A Escobar, James Luck, Yevhenii Averianov, Jonathan Ducore, Maria Fernanda López Fernández, Adam Giermasz, Daniel P Hart, Janna Journeycake, Craig M Kessler, Cindy Leissinger, Johnny N Mahlangu, Laura Villarreal Martinez, Wolfgang Miesbach, Ismail Haroon Mitha, Doris Quon, Mark T Reding, Jean-François Schved, Oleksandra Stasyshyn, Kateryna V Vilchevska, Michael Wang, Jerzy Windyga, W Allan Alexander, Ahmad Al-Sabbagh, Daniel Bonzo, Ian S Mitchell, Thomas A Wilkinson, Cédric Hermans
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors. Haemophilia : the official journal of the World Federation of Hemophilia 27 (6) (2021)
Mark T Reding, Ingrid Pabinger-Fasching, Pal Andre Holme, Lone Poulsen, Claude G Negrier, Pavani Chalasani, Monika Maas Enriquez, Maria Wang, Karina Meijer, Maria Elisa Mancuso, Shadan Lalezari
Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study. Haemophilia : the official journal of the World Federation of Hemophilia 27 (3) (2021)
Skye J Peltier, Marshall A Mazepa, Rebecca L Freese, Shannon F Nelson, Susan L Kearney, Mark T Reding
Opioid exposure in haemophilia patients is common and underreported. Haemophilia : the official journal of the World Federation of Hemophilia 26 (2) (2020)
Mark T Reding, Ingrid Pabinger-Fasching, Shadan Lalezari, Elena Santagostino, Maria Elisa Mancuso
Target joint resolution in patients with haemophilia A receiving long-term prophylaxis with BAY 94-9027. Haemophilia : the official journal of the World Federation of Hemophilia 26 (4) (2020)